Celldex Therapeutics, INC 8-K filings

Celldex Therapeutics announces the planned retirement of CFO Sam Martin, effective March 31, 2027, with a search for his successor underway.

Celldex Therapeutics stockholders approved the election of directors and an increase of 3.4 million shares to the 2021 Omnibus Equity Incentive Plan.

Celldex Therapeutics has priced an underwritten public offering of 10,345,000 shares of common stock at $29.00 per share to raise approximately $282 million in net proceeds.

Celldex Therapeutics announced the early completion of enrollment for its Phase 3 CSU studies, with topline data expected in Q4 2026, alongside increased R&D expenses and a higher net loss for 2025.

Celldex Therapeutics announced positive Phase 2 clinical data for barzolvolimab in chronic urticarias and CDX-622, alongside Q3 2025 financial results and a new Chief Commercial Officer.

Celldex Therapeutics announced that its Phase 2 study of Barzolvolimab in Eosinophilic Esophagitis met its primary endpoint of mast cell depletion but failed to show clinical improvement, leading to a halt in EoE development.

Celldex Therapeutics announced its second quarter 2025 financial results and provided a corporate update, highlighting strong progress in its barzolvolimab clinical programs and initiating Phase 3 trials.

Celldex Therapeutics, Inc. announced the results of its 2025 Annual Meeting of Stockholders, including the election of directors, ratification of auditors, approval of an expanded equity incentive plan, and the appointment of a new Board Chair.

Celldex Therapeutics announced its Q1 2025 financial results, highlighting progress in its pipeline, particularly with barzolvolimab and CDX-622.

Celldex Therapeutics announces its fourth quarter and year-end 2024 financial results, highlighting progress in its clinical programs, particularly barzolvolimab, and the initiation of a Phase 1 study for CDX-622.

Celldex Therapeutics announced positive results from its Phase 2 trials of barzolvolimab and provided an update on its clinical pipeline, including the advancement of a new bispecific antibody.

Celldex Therapeutics announced positive results from its Phase 2 trials for barzolvolimab and initiated Phase 3 studies, while also reporting a strong cash position to support ongoing development.

Celldex Therapeutics' stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan, increasing the share reserve by 3.2 million shares and raising the non-employee director award limit.

Celldex Therapeutics announced its first quarter 2024 financial results, highlighted by a strong cash position and progress in its clinical programs, particularly barzolvolimab.

Celldex Therapeutics has announced the pricing of an upsized public offering of 8,520,000 shares of its common stock at $47.00 per share, expected to close around March 5, 2024.

Celldex Therapeutics announced positive results from its barzolvolimab clinical trials and provided a financial update, highlighting progress in mast cell mediated disease treatments.